MBRX Moleculin Biotech Inc
Company Analysis
Latest News
🟢 Moleculin Biotech is trading 5.5% up in after-hours trading with no identified catalyst
Moleculin Biotech is trading 5.5% higher in after-hours trading at $0.47, versus the regular-session close of $0.45; no catalyst was identified. - The regular...
🔴 Moleculin Biotech is trading 5.5% down today amid biotech-sector weakness
Moleculin Biotech is trading at $0.45, down 5.52%, with biotech-sector weakness a possible contributing factor. - No clear company-specific catalyst was...
🔴 Moleculin Biotech is trading 5% down; no clear company-specific catalyst identified
Moleculin Biotech is trading at $0.46, down 5.14%, with no clear company-specific catalyst identified for the October 5 decline. - The latest reported company...
🔴 Moleculin Biotech is trading 5% down as no clear company-specific cause was identified
Moleculin Biotech is trading 5% lower at $0.48, with no clear company-specific explanation identified for the October 2 move. - Its latest listed releases were...
🔴 Moleculin Biotech is trading 5% down with no company-specific catalyst identified
Moleculin Biotech is trading 5.02% down at $0.50 on September 30, 2026, with no company-specific announcement found to explain the decline. - The latest major...
MBRX Completes Enrollment in Pivotal AML Trial, Data Readout Expected Q1 2027
Moleculin Biotech, Inc. announced it has completed and closed patient enrollment for Part A of its pivotal Phase 2/3 MIRACLE trial. The study is evaluating its...
🔴 Moleculin Biotech is trading 5.9% down
Moleculin Biotech is trading 5.9% lower at $0.54; the provided information does not establish a catalyst for the decline. - Shares closed down 5.42% at $0.57...
🟢 Moleculin Biotech is trading 5.4% up in pre-market on strong Annamycin cardiac safety findings
Moleculin Biotech is trading $0.60, up 5.4%, in pre-market on September 29, following its September 28 announcement of peer-reviewed Annamycin cardiac safety...
Moleculin Announces Publication of Positive Cardiac Safety Data for Annamycin
Moleculin Biotech announced the publication of a peer-reviewed analysis in "Frontiers in Cardiovascular Medicine" detailing favorable cardiac safety findings...
🔴 Moleculin Biotech is trading 5.25% down with no clear company-specific catalyst
Moleculin Biotech is trading at $0.57, down 5.25%, with no clear company-specific catalyst identified for the September 28 decline. - Its September 25...
🔴 Moleculin Biotech is trading 10.72% down in pre-market
Moleculin Biotech is trading 10.72% lower in pre-market at $0.54, with no clear company-specific catalyst identified for the September 28 decline. - Its...
🔴 Moleculin Biotech is trading 10.72% down in pre-market — no clear company-specific catalyst identified
Moleculin Biotech is trading at $0.54, down 10.72% in pre-market, with no clear company-specific catalyst identified. - Its latest announcement, on September...
🔴 Moleculin Biotech is trading 10.72% down in pre-market
Moleculin Biotech is trading at $0.54, down 10.72% in pre-market, with no clear company-specific catalyst identified. - Its latest company announcement, on...
🔴 Moleculin Biotech is trading 10.72% down in pre-market
Moleculin Biotech is trading at $0.54, down 10.72% in pre-market, with no clear company-specific catalyst identified for the September 28 decline. - The...
🔴 Moleculin Biotech is trading 6.4% down in after-hours trading
Moleculin Biotech is trading 6.4% lower at $0.56 in after-hours trading; no clear company-specific catalyst for the decline was identified. - Shares closed at...
Moleculin Biotech Reports New Preclinical Data for Annamycin in Pancreatic Cancer
Moleculin Biotech, Inc. (MBRX) announced new preclinical data for its lead drug candidate, Annamycin (naxtarubicin), showing its antitumor activity in...
MBRX Rallies 10% Ahead of Pancreatic Cancer Data — But Can a Sub-$12 Million Company Outrun a Delisting Clock?
Shares of Moleculin Biotech surged 10.2% to $0.62 on September 25 as traders positioned ahead of an embargoed cancer-research abstract set to drop at 1:00 p.m....
🟢 Moleculin Biotech is trading 10.25% up today ahead of AACR Annamycin pancreatic-cancer data
Moleculin Biotech is trading 10.25% higher at $0.62 as investors anticipate new Annamycin pancreatic-cancer data at AACR. - The abstract is scheduled for...
🟢 Moleculin Biotech is trading 5% up today ahead of AACR Annamycin pancreatic-cancer data
Moleculin Biotech is trading at $0.60, up +5.15%, ahead of the September 25–28 AACR conference, where new Annamycin pancreatic-cancer data will be...
🟢 Moleculin Biotech is trading 5.59% up today amid likely speculative trading
Moleculin Biotech is trading at $0.56, up 5.59%, with recent volatility and speculative trading appearing more likely than a confirmed catalyst. - The rebound...